Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

404
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
404
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

262
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
262
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

229
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
229
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

325
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
325
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

644
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
644
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

775
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
775

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of barbed suture vs. conventional suture on postoperative recovery and uterine integrity in patients undergoing laparoscopic myomectomy.

Frontiers in surgery·2025
Same author

The impact of positive psychological capital on health literacy among college students: The mediating role of health behavior intention.

Acta psychologica·2025
Same author

Establishment of a liver-specific Albumin-Cre recombinase transgenic golden hamster model using gRosa26-Targeted dual-fluorescent reporter system for hepatocyte-specific genetic manipulation.

Biochemical and biophysical research communications·2025
Same author

Internalized Stigma in Patients With Schizophrenia in Rural China: Prevalence and Associated Factors.

The International journal of social psychiatry·2025
Same author

Arbitrary polarization and rotation multiplexed metasurface hologram.

Nanophotonics (Berlin, Germany)·2025
Same author

Treatment outcomes of zanubrutinib-based regimen in newly diagnosed patients with MYC/BCL2 double-expressor diffuse large B-cell lymphoma: a retrospective multicenter real-world study.

Annals of hematology·2025

Related Experiment Video

Updated: Oct 9, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.4K

Increased SERPINA3 Level Is Associated with Ulcerative Colitis.

Jingwei Zhang1,2, Wei Wang1, Shenglong Zhu1,3

  • 1Wuxi School of Medicine, Jiangnan University, Wuxi 214122, China.

Diagnostics (Basel, Switzerland)
|December 24, 2021
PubMed
Summary

Serine peptidase inhibitor, clade A, member 3 (SERPINA3) is elevated in ulcerative colitis (UC) and may serve as a biomarker. Silencing SERPINA3 reduces inflammation, suggesting it as a potential therapeutic target for UC.

Keywords:
SERPINA3biomarkerulcerative colitis

More Related Videos

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.3K
Investigating Intestinal Inflammation in DSS-induced Model of IBD
08:43

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Published on: February 1, 2012

67.8K

Related Experiment Videos

Last Updated: Oct 9, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.4K
Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.3K
Investigating Intestinal Inflammation in DSS-induced Model of IBD
08:43

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Published on: February 1, 2012

67.8K

Area of Science:

  • Gastroenterology
  • Molecular Biology
  • Immunology

Background:

  • Ulcerative colitis (UC) is a chronic, incurable intestinal disease with poorly understood pathogenesis.
  • There is an urgent need for novel biomarkers and therapeutic targets for effective UC treatment.
  • Identifying key molecular players in UC pathogenesis is crucial for advancing treatment strategies.

Purpose of the Study:

  • To identify novel biomarkers and potential therapeutic targets for ulcerative colitis (UC).
  • To investigate the role of the SERPINA3 gene in the pathogenesis of UC.
  • To validate SERPINA3 as a potential biomarker and drug target for UC.

Main Methods:

  • Analysis of gene expression profile GSE38713 from the GEO database.
  • Differential gene expression analysis using R software and Gene Ontology enrichment via Metascape.
  • Validation in colitis model mice and in-vitro intestinal epithelial models, including gene silencing experiments.

Main Results:

  • SERPINA3 gene expression was significantly increased in UC patient samples and experimental colitis models.
  • SERPINA3 expression correlated with other inflammatory factors, and ROC analysis suggested its potential as an active UC biomarker.
  • Silencing SERPINA3 in an in-vitro inflammatory model reduced the mRNA levels of inflammatory factors.

Conclusions:

  • SERPINA3 is upregulated in ulcerative colitis and associated with inflammation.
  • SERPINA3 shows potential as a diagnostic biomarker for active UC.
  • Targeting SERPINA3 may offer a novel therapeutic strategy for UC treatment.